PRTA

Prothena Corporation plc

27.38 USD
-0.64 (-2.28%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Prothena Corporation plc stock is down -19.64% since 30 days ago. The next earnings date is May 2, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 58.33% of the previous 11 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 10 CALLs. 25% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
18 Jan 15:45 19 Jan, 2024 30.00 CALL 455 3453
18 Jan 16:04 19 Jan, 2024 30.00 CALL 510 3453
19 Jan 17:11 19 Jan, 2024 30.00 CALL 120 2499
23 Jan 16:11 17 May, 2024 50.00 CALL 283 0
23 Jan 18:59 17 Jan, 2025 45.00 CALL 120 1
30 Jan 19:13 16 Feb, 2024 30.00 CALL 139 156
02 Feb 17:52 15 Mar, 2024 25.00 CALL 100 3
08 Feb 20:57 15 Mar, 2024 25.00 CALL 100 182
08 Feb 20:59 15 Mar, 2024 25.00 CALL 73 182
15 Feb 19:23 17 May, 2024 35.00 CALL 88 35

About Prothena Corporation plc

Prothena Corporation plc focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, is in clinical trials for Parkinson's disease; PRX004, which completed Phase I clinical trial.

  • JP Morgan
    Fri Feb 16, 14:56
    buy
    confirm
  • RBC Capital
    Fri Feb 16, 12:41
    hold
    confirm
  • Bank of America
    Tue Jan 30, 08:04
    hold
    downgrade
  • RBC Capital
    Thu Jan 25, 11:50
    hold
    confirm